SYnAbs' vision is to fill the gap in the marketplace for innovative antibodies against poor immunogenic compounds and complex antigens. Targeting lipids, peptides, neo-epitopes, toxins, epigenetic modifications and polysaccharides, SYnAbs has developed strong expertise in immunology to break immunotolerance in rat and guinea pig species to generate unique monoclonal antibodies of extreme specificity and higher affinity.